Compare WHD & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHD | NUVB |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.9B |
| IPO Year | 2018 | N/A |
| Metric | WHD | NUVB |
|---|---|---|
| Price | $52.82 | $6.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $50.20 | $10.44 |
| AVG Volume (30 Days) | 721.7K | ★ 6.3M |
| Earning Date | 02-25-2026 | 03-05-2026 |
| Dividend Yield | ★ 1.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.52 | N/A |
| Revenue | ★ $1,089,969,000.00 | $26,748,000.00 |
| Revenue This Year | N/A | $616.63 |
| Revenue Next Year | $33.36 | $202.59 |
| P/E Ratio | $21.11 | ★ N/A |
| Revenue Growth | N/A | ★ 1137.19 |
| 52 Week Low | $33.20 | $1.54 |
| 52 Week High | $65.35 | $9.75 |
| Indicator | WHD | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 72.39 | 29.46 |
| Support Level | $51.35 | $6.07 |
| Resistance Level | $53.52 | $6.63 |
| Average True Range (ATR) | 1.50 | 0.53 |
| MACD | 0.29 | -0.39 |
| Stochastic Oscillator | 83.48 | 11.03 |
Cactus Inc is engaged in the designing, manufacturing, and sale of wellheads and pressure control equipment. Its principal products include Cactus SafeDrill wellhead systems, conventional wellheads, and production valves among others. The company also provides mission-critical field services, including service crews to assist with the installation, maintenance, and safe handling of the wellhead and pressure control equipment, as well as repair services for equipment that it sells or rents. It sells or rents its products principally for onshore unconventional oil and gas wells that are utilized during the drilling, completion (including fracturing), and production. The company has two operating segments; Pressure Control, which generates key revenue and Spoolable Technologies.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.